ArticleCureus2026
Role of the Fungal Serological Marker Galactomannan Antigen in the Diagnosis of Invasive Fungal Infection: A Three-Year Retrospective Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives Invasive fungal infections (IFIs) are the most prevalent potentially fatal opportunistic mycoses in immunocompromised individuals. Early detection is essential for treating these patients. Biomarkers, measured in blood or other clinical samples, are effective supplements to conventional pathologic and microbiologic diagnostic methods for IFIs. We conducted this study to determine the positivity of serum galactomannan (GM) in clinically diagnosed IFI. Also, we assessed the diagnostic power of GM for predicting invasive aspergillosis (IA), the most common cause of IFIs. Methodology This retrospective study analyzed clinically diagnosed patients with IFIs admitted to Kalinga Institute of Medical Sciences (KIMS), Bhubaneswar, India, from January 2023 to December 2025. The study included the blood samples received for serum GM antigen testing during the study period. We evaluated the diagnostic performance of the GM antigen. We also plotted the receiver operating characteristic (ROC) curve and determined the area under the curve (AUC). Results We analyzed data from 172 clinically diagnosed patients with IFIs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.